All In Biotech

Drug Trial Radar · NCT04680026

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

A Phase 2, Two-Stage, Serial Cohort Dose Escalation and Expansion Study of a Single Intravenous Infusion of HBI 3000 for the Conversion of Atrial Fibrillation (AF) of Recent Onset

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 1, 2021

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
HUYABIO International, LLC.Industry
Sponsor type
Industry
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversion of patients with recent-onset atrial fibrillation (AF). Stage A is open label and all patients will receive HBI-3000. In each of three dose cohorts, up to 10 patients will receive HBI-3000 by IV infusion (30 minutes). Three different dose levels are planned to be administered serially, lowest to highest, with assessment of safety, tolerability, and efficacy prior to proceeding to the next dose level group. Following Stage A, the iDMC will recommend up to two doses of HBI-3000 to be further explored in Stage B. Stage B is a serial, randomized, double-blind and placebo-controlled cohort of two different doses of HBI-3000, with a dose decision after the first cohort. Stage B will be powered to show a difference between HBI-3000 and placebo in conversion rate at each of the two dose levels.

Conditions

  • Atrial Fibrillation

Interventions

  • HBI-3000Drug

    Small molecule, multi-ion channel blocker

  • PlaceboDrug

    Normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by the incidence of adverse events (AEs)Time frame: 30 days
  2. Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by changes in heart rate (HR)Time frame: 90 minutes
  3. Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by change in blood pressure (BP)Time frame: 90 minutes
  4. Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by ECG interval changes above a specific levelTime frame: 24 hours
  5. The efficacy of intravenously (IV) administered HBI-3000 as measured by the proportion of patients with AF of recent onset who convert to SRTime frame: 120 minutes

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • NCH Research Institute

    Naples, Florida

  • Prairie Education & Research

    Springfield, Illinois

  • North Mississippi Medical Center

    Tupelo, Mississippi

  • CHRISTUS Trinity Mother Frances Hospital - Tyler

    Tyler, Texas

  • University Clinical Center of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • Montreal Heart Institute

    Montreal, Quebec, Canada

  • Centre hospitalier de L'Universite de Montral (CHUM)

    Montreal, Quebec, Canada

  • Centre integre de sante et de services sociaux de Lanaudiere - Hopital Pierre-Le Gardeur

    Terrebonne, Quebec, Canada

  • Waikato Hospital

    Hamilton, New Zealand

  • Wellington Regional Hospital

    Wellington, New Zealand

  • University Clinical Center of Serbia

    Belgrade, Serbia

  • Dedinje Institute for Cardiovascular Diseases

    Belgrade, Serbia

  • University Hospital Medical Center Bezanijska kosa

    Belgrade, Serbia

  • Niš University Clinical Center

    Niš, Bulevar Doktora, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.